For patients with type 2 diabetes who need large doses of insulin, adding an SGLT2 inhibitor to insulin therapy can mean much less insulin is needed according to new research. Patients with daily insulin doses between 101 and 200 units experienced an insulin dose reduction of 17 units/day with the addition of canagliflozin (brand name Invokana) to their therapy, researchers found. Read more